Drug inhalation company MAP Pharma files for $86M IPO
MAP Pharmaceuticals, a Mountain View, Calif., developer of reformulated drugs for inhalation, has filed to raise up to $86 million in an initial public offering.
See VentureBeat LifeSciences story here.
Next Story: IBM sees big future in 3D, but probably not in Second Life
Previous Story: SupplyFrame, a search engine for gadgets, electrical components
About the Author, Matt Marshall
Matt Marshall is editor and CEO of VentureBeat. Follow him on Twitter at @mmarshall, and follow VentureBeat on Twitter at @venturebeat.